Sogroya^® vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)

Results of REAL 4, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly Sogroya® compared to once daily Norditropin® in growth-hormone naïve pre-pubertal children with growth hormone deficiency.

Sogroya^® vs. Once-daily Growth Hormone - Phase 2 Pediatric Patients with Growth Hormone Deficiency (REAL 3)

Overview of REAL 3, the Phase 2 dose-finding trial investigating efficacy and safety of once-weekly Sogroya® compared to once daily Norditropin® FlexPro® injection in growth-hormone naïve pre-pubertal children with growth hormone deficiency.

Sogroya^® Treatment-naive Adults with Growth Hormone Deficiency (REAL 1)

Summary of REAL 1, the pivotal Phase 3 study evaluating the efficacy and safety of once-weekly Sogroya® compared to once-weekly placebo or once-daily Norditropin® in adults with growth hormone deficiency.

Albumin Interactions with Sogroya^®

An overview of expected albumin interactions from hypoalbuminemia or other protein-bound drugs based on the mechanism of protraction (albumin-binding) used by Sogroya®

Growth Hormone Deficiency Practice Aids (IME Content)

Various practice aids for HCPs, including a chart detailing the patient experience / perspective, a 9-item shared decision-making questionnaire, and information and questionnaire pertaining to the LAuGH clinical trial / enrollment evaluation,

Growing Pains: Overcoming Challenges in the Management of Adult Growth Hormone Deficiency (IME content)

Overview of adult growth hormone deficiency, available and emerging treatment options, and healthcare transition challenges with long-term management